FOR IMMEDIATE RELEASE
American Heart Association consortium advances development of evidence-based health tech solutions
Jericho, NY, September 18’th, 2024 – ImaCor, the inventor of hTEE (hemodynamic transesophageal echocardiography), has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
The Innovators’ Network is a health care technology consortium that connects entrepreneurs, providers, researchers and payers. Innovators’ Network members also have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.
“The Center aims to advance the rapid, efficient, and effective development of healthcare technology,” said Robert A. Harrington, M.D., FAHA, volunteer past president of the American Heart Association (2019-2020), chair of the American Heart Association’s Health Tech Advisory Group for the Center and the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”
“ImaCor’s One Touch Hemodynamic UltrasoundTM provides a new option for real-time monitoring of cardiac function,” said Scott L. Roth, MD., Founder and CEO. “We are excited to be a part of the Innovators’ Network to develop models and studies that support integration of this important innovation into ICU team-based care.”
About ImaCor
ImaCor, Inc. designs, manufactures, and distributes a mobile transesophageal echo (TEE) monitoring platform cleared by the FDA for use with a miniaturized, disposable TEE probe. This probe, called the ClariTEE®, is FDA-cleared to remain in place for up to 72 hours, enabling continuous, direct visualization of patient cardiac filling and function in the ICU.
ImaCor’s new (FDA pending) AI-driven One Touch Hemodynamics™, an automated measurements platform, provides ICU care teams with one-touch access to preload and contractility data. This technology supports rapid, ongoing decision-making, transforming care for sepsis, post-surgery, and cardiac support patients.
###
MEDIA CONTACT:
Jenn Kujawski
jenn@imacorinc.com
516.393.0970 x402